» Articles » PMID: 33681184

MiR-199a-5p-HIF-1α-STAT3 Positive Feedback Loop Contributes to the Progression of Non-Small Cell Lung Cancer

Overview
Specialty Cell Biology
Date 2021 Mar 8
PMID 33681184
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Non-small cell lung cancer (NSCLC) is the most common malignancy worldwide. MiR-199a-5p has been reported to play important roles in multiple tumors, inclusive of NSCLC. However, little is definitively known pertaining to its explicit mechanism of action in NSCLC. The expressions of miR-199a-5p and hypoxia-inducible factor-1α (HIF-1α) mRNA were quantified employing qRT-PCR. H1299 and A549 cells were transiently transfected with miR-199a-5p mimics or inhibitors. Then, CCK-8 assays, flow cytometry analysis, and Transwell assay were performed for detecting cell proliferation, cell cycle, apoptosis, migration, and invasion of NSCLC cells, respectively. HIF-1α, signal transducer and activator of transcription 3 (STAT3), and p-STAT3 expressions were detected via Western blotting. Bioinformatic analysis and dual-luciferase assay were performed to investigate the interactions among miR-199a-5p, HIF-1α, and STAT3. Xenograft models were established with nude mice for further analyzing the bevacizumab resistance of NSCLC cells. MiR-199a-5p expression was markedly attenuated in NSCLC tissues and cell lines. Overexpression of miR-199a-5p repressed the proliferation, migration, and invasion but induced the apoptosis of NSCLC cells. HIF-1α was identified as a direct target of miR-199a-5p. There was a positive feedback loop among miR-199a-5p, HIF-1α, and STAT3. Co-transfection of HIF-1α or STAT3 overexpression plasmids counteracted the effects of miR-199a-5p. experiments indicated that the feedback loop was in association with the bevacizumab resistance of NSCLC cells. MiR-199a-5p blocked the progression of NSCLC and sensitized NSCLC cells to bevacizumab by suppressing HIF-1α and STAT3, while the HIF-1α/STAT3 axis suppressed the expression of miR-199a-5p, which forms a positive feedback loop to promote the sustaining progression of NSCLC.

Citing Articles

Analysis of the correlation between the levels of HIF-1α and miR-199a in lesions and the psoriasis severity index.

Miao G, Pan J, Wang L, Li F Postepy Dermatol Alergol. 2024; 41(5):521-524.

PMID: 39606598 PMC: 11589632. DOI: 10.5114/ada.2024.143495.


AAV-mediated combination gene therapy of inducible Caspase 9 and miR-199a-5p is therapeutic in hepatocellular carcinoma.

Pathak S, Singh V, Kumar G N, Jayandharan G Cancer Gene Ther. 2024; 31(12):1796-1803.

PMID: 39385010 DOI: 10.1038/s41417-024-00844-x.


MicroRNA-450b-5p modulated RPLP0 promotes hepatocellular carcinoma progression via activating JAK/STAT3 pathway.

Meng Y, Huang X, Zhang G, Fu S, Li Y, Song J Transl Oncol. 2024; 50:102150.

PMID: 39383650 PMC: 11490897. DOI: 10.1016/j.tranon.2024.102150.


Advances in Predictive Biomarkers for Anti-Angiogenic Therapy in Non-Small Cell Lung Cancer.

Zhao W, Jiang J Cancer Control. 2024; 31:10732748241270589.

PMID: 39192835 PMC: 11363049. DOI: 10.1177/10732748241270589.


miR-199a-5p targets DUSP14 to regulate cell proliferation, invasion and stemness in non-small cell lung cancer.

Zheng Y, Yang C, Xie S, Liu D, Wang H, Liu J Heliyon. 2024; 10(8):e29102.

PMID: 38644862 PMC: 11033068. DOI: 10.1016/j.heliyon.2024.e29102.


References
1.
Tu Z, He D, Deng X, Xiong M, Huang X, Li X . An eight-long non-coding RNA signature as a candidate prognostic biomarker for lung cancer. Oncol Rep. 2016; 36(1):215-22. DOI: 10.3892/or.2016.4817. View

2.
Brody R, Zhang Y, Ballas M, Siddiqui M, Gupta P, Barker C . PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. Lung Cancer. 2017; 112:200-215. DOI: 10.1016/j.lungcan.2017.08.005. View

3.
Adachi M, Cui C, Dodge C, Bhayani M, Lai S . Targeting STAT3 inhibits growth and enhances radiosensitivity in head and neck squamous cell carcinoma. Oral Oncol. 2012; 48(12):1220-6. PMC: 3734563. DOI: 10.1016/j.oraloncology.2012.06.006. View

4.
Assoun S, Brosseau S, Steinmetz C, Gounant V, Zalcman G . Bevacizumab in advanced lung cancer: state of the art. Future Oncol. 2017; 13(28):2515-2535. DOI: 10.2217/fon-2017-0302. View

5.
Bradbury P, Sivajohanathan D, Chan A, Kulkarni S, Ung Y, Ellis P . Postoperative Adjuvant Systemic Therapy in Completely Resected Non-Small-Cell Lung Cancer: A Systematic Review. Clin Lung Cancer. 2017; 18(3):259-273.e8. DOI: 10.1016/j.cllc.2016.07.002. View